J. Wang

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Roy S. Herbst, Yan Sun, S. Korfee et al. · Journal of Clinical Oncology · 2009 · 76 citations

Surgical Oncology, Cancer Management, Pathology +17

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

Hong Wu, Chen Hu, Ellen Weisberg et al. · Leukemia · 2015 · 46 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study

Tony Mok, Yujun Wu, Ken Nakagawa et al. · Annals of Oncology · 2014 · 46 citations · Full text

Impress Study, Medicine, Gefitinib/chemotherapy Vs Chemotherapy +8